KalVista Pharmaceuticals (NASDAQ:KALV) Downgraded by Zacks Investment Research to “Sell”

Zacks Investment Research lowered shares of KalVista Pharmaceuticals (NASDAQ:KALVGet Rating) from a hold rating to a sell rating in a research report released on Wednesday, Zacks.com reports.

According to Zacks, “KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which are in clinical stage. KalVista Pharmaceuticals, Inc., formerly known as Carbylan Therapeutics, Inc., is headquartered in Cambridge, United States. “

KALV has been the subject of a number of other research reports. Needham & Company LLC reduced their target price on KalVista Pharmaceuticals from $48.00 to $42.00 and set a buy rating for the company in a report on Friday, March 11th. Roth Capital reaffirmed a buy rating on shares of KalVista Pharmaceuticals in a report on Tuesday, March 8th. Finally, HC Wainwright reaffirmed a buy rating and issued a $48.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, March 11th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of Buy and an average price target of $47.00.

KalVista Pharmaceuticals stock opened at $14.81 on Wednesday. The stock has a fifty day simple moving average of $15.37 and a two-hundred day simple moving average of $15.19. KalVista Pharmaceuticals has a 12 month low of $10.79 and a 12 month high of $30.70.

KalVista Pharmaceuticals (NASDAQ:KALVGet Rating) last posted its earnings results on Thursday, March 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.91) by ($0.01). Equities research analysts forecast that KalVista Pharmaceuticals will post -3.45 earnings per share for the current year.

In related news, CEO Thomas Andrew Crockett sold 10,000 shares of KalVista Pharmaceuticals stock in a transaction on Wednesday, March 9th. The stock was sold at an average price of $17.07, for a total value of $170,700.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 6.40% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Monashee Investment Management LLC purchased a new position in shares of KalVista Pharmaceuticals in the third quarter valued at about $2,181,000. Two Sigma Advisers LP lifted its position in shares of KalVista Pharmaceuticals by 550.2% in the third quarter. Two Sigma Advisers LP now owns 120,422 shares of the specialty pharmaceutical company’s stock valued at $2,101,000 after acquiring an additional 101,900 shares in the last quarter. Suvretta Capital Management LLC increased its holdings in shares of KalVista Pharmaceuticals by 29.6% in the third quarter. Suvretta Capital Management LLC now owns 1,543,284 shares of the specialty pharmaceutical company’s stock worth $26,930,000 after purchasing an additional 352,183 shares during the last quarter. Barclays PLC increased its holdings in shares of KalVista Pharmaceuticals by 105.2% in the third quarter. Barclays PLC now owns 10,404 shares of the specialty pharmaceutical company’s stock worth $181,000 after purchasing an additional 5,335 shares during the last quarter. Finally, Trexquant Investment LP bought a new stake in shares of KalVista Pharmaceuticals in the third quarter worth about $334,000.

About KalVista Pharmaceuticals (Get Rating)

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Read More

Get a free copy of the Zacks research report on KalVista Pharmaceuticals (KALV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.